AUCTORES
Globalize your Research
Research Article
*Corresponding Author: Omnia Kamel, Cardiology Department, Aswan Heart centre, Egypt.
Citation: Omnia Kamel, Mohamed Elewa, Mohamed Sharief, Ahmed G. Elewa, Omar M. Elhodhod, et al., (2024), Pulsed Field Ablation of Atrial Fibrillation: Concept, Evidence and Available Technologies Where do we stand in 2024? Cardiology Research and Reports, 6(3); DOI:10.31579/2692-9759/126
Copyright: © 2024, Omnia Kamel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 12 April 2024 | Accepted: 22 April 2024 | Published: 06 May 2024
Keywords: atrial fibrillation; catheter ablation; pulsed field ablation; pulmonary vein isolation
Abstract
Catheter ablation (CA) has been commonly used in treatment of symptomatic patients with Atrial Fibrillation (AF) with Pulmonary vein isolation (PVI) being considered as the cornerstone of AF ablation procedure (1). However, there are major challenges facing PVI using current CA technologies including the durability of PVI, risk of Pulmonary veins (PV) reconnection, collateral damage especially phrenic nerve injury and oesopahguial injury (2). Therefore, better technology was needed to improve efficacy and safety. Pulsed field ablation (PFA) has emerged over last few years as new ablation modality for the treatment of AF using non-thermal energy and irreversible electroporation.
This review provides an update on concept, current evidence, gap in evidence and available technology for PFA of AF.
AFL = atrial flutter
AF = atrial fibrillation
AT = atrial tachycardia
CA = Catheter ablation
CMR = Cardiac magnetic resonance
CT= computerised tomography
CTI = cavotricuspid isthmus
IRE = irreversible electroporation
LGE = late gadolinium enhancement
OGD = oesophagogastroduodenoscopy
PEF = pulsed electrical field
PFA = pulsed field ablation
PVI = Pulmonary vein isolation
PV = Pulmonary vein
RF = radiofrequency
VLCC = variable loop circular catheter
PVI using radiofrequency or cryoablation technologies is currently recommended for management of symptomatic AF patients either as first line rhythm control strategy or after failed one or more antiarrhythmic drugs (3). However, catheter ablation can be associated with complications including pulmonary vein (PV) stenosis, phrenic nerve injury, cerebrovascular injury, and atrioesophageal fistula (2). Maintaining the balance between the efficacy and safety of AF ablation procedure remains a challenge. The new emerging Pulsed field ablation (PFA) technology has been proposed to offer better safety and efficacy advantages as compared to currently used catheter ablation technologies due to the minimal thermal energy imparted to target tissue and the ability to create transmural and contiguous lesions through Irreversible electroporation (IRE) (4,5).
PFA is an irreversible form of electroporation via applying high voltage electrical fields which induce pore formation within the lipid layer of the cell membrane resulting in homeostatic changes and cell death. This technology has been used as a treatment modality to induce targeted cell death in other medical fields such as Oncology and it is now considered as an alternate energy source for treatments of cardiac arrhythmias.
First attempt in ablation in human was described in 1982 by Melvin Scheinman and his colleagues delivering single monophasic shocks of high amplitude for atrioventricular nodal ablation to treat supraventricular arrhythmias in five patients with recurrent bouts of supraventricular tachycardia resistant to both conventional and experimental drugs. However, the extent of the ablated tissue was hardly to control, and the approach itself has put the patient at risk of barotrauma. Complete atrioventricular (AV) block was produced in all, one patient died suddenly six weeks after shock therapy, and the remainder had complete AV block with follow-up intervals ranging from four to 12 months (6).
Over years, there was growing evidence towards using of PFA as a non-thermal source of energy in ablation of cardiac arrhythmias having the following advantages:
a. Tissue Specificity:
Cardiomyocytes have lower electrical thresholds as compared to other tissues making pulsed field ablation highly specific for cardiomyocytes reducing risk of collateral damage. Moreover, direct application of pulsed field energy (PFE) to esophageal tissue resulted only in minimal damage minimizing the risk of post-ablation atrio-esophageal fistula and the same applies for phrenic nerve affection (7,8). In addition, pre-clinical studies have shown preserved structure and function of blood vessels even with direct application despite transient luminal narrowing that can be attributed to vascular spasm (9–11).
b.Time factor:
Standard ablation techniques usually require several seconds to minutes to achieve steady‐state temperature gradients (12). Whereas the effect of PFA is almost instantaneous. A single PFA delivery is usually accomplished within one heartbeat, and a lesion is typically created with 3 to 4 PFA deliveries and if a circumferential electrode catheter is employed, vein isolation can be achieved within four heartbeats. Practically, it is anticipated that single vein isolation should be achievable routinely within 1 to 2 minutes and hence, a total procedure duration of 60 to 90 minutes for four PV isolation should be easily achievable in most of the cases using PFA (13,14).
c.Temperature independence:
Being a non-thermal modality, the depth of lesions is mainly affected by the pattern of energy delivery which can be adjusted by multiple parameters including voltage, frequency, polarity, number of pulses/trains, pulse cycle length, duty cycle, pulse shape, phasicity, inter-pulse delay and inter-phase delay in addition to other factors such as tissue characteristics, heterogeneity as well as fiber orientation (15–21).
a) Head-to-head comparison and randomised controlled studies
Although multiple observational studies have been conducted on different PFA systems, only few head-to-head comparison studies have been conducted showing similar procedure efficacy and shorter procedure time (22,23).
ADVENT trial was the first randomized, single-blind, noninferiority head-to-head study published in 2023 showing the noninferiority of PFA versus conventional RF ablation in patients with paroxysmal AF as regards freedom from a composite of initial procedural failure, documented atrial tachyarrhythmia after a 3-month blanking period, antiarrhythmic drug use, cardioversion, or repeat ablation and device- and procedure-related serious adverse events at 1 year (24). The SINGLE SHOT CHAMPION trial is another ongoing randomised controlled non-inferiority trial comparing the FARAPULSE PFA versus the Arctic Front Cryoballoon (Medtronic) in patients with paroxysmal AF undergoing PVI (25).
b) Durability of lesions
Moving beyond the “honeymoon phase” of PFA, an important question has arisen regarding the durability of lesions despite the very high perfect acute procedural success with an excellent safety profile reported at the early trials. Beyond the border created by PFA where there is permanent damage, there is a penumbra of tissue with reversible electroporation which demonstrates loss of electrical activity in the acute stage despite retaining residual viability. Upon recovery of membrane function, this tissue can regain electrophysiological function; thus, hampering lesion durability and hence acute disappearance of local electrograms immediately after pulse delivery may not guarantee lesion durability highlighting the need for setting reliable metrics for defining successful durable lesion delivery (26).
Tancredi Magni and his colleagues reported recurrence rate of 3.1% within one-year in a cohort of 447 patients underwent AF PFA, 50% of the recurrences were AF, 14.3% had AFL and the remaining had both (27).
In the recent multinational retrospective registry, MANIFEST-PF which included 1568 patients underwent PFA for paroxysmal or persistent AF, the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was 78.1% with a more common clinical effectiveness in patients with paroxysmal AF versus persistent AF (81.6% versus 71.5%; P=0.001) (28). Furthermore, redo procedures confirmed a durable isolation in 71% of PVs in the recurrent cases in EU-PORIA registry (European Real-world Outcomes with Pulsed Field Ablation in Patients with Symptomatic Atrial Fibrillation) (29). Prior operator experience with cryoballoon ablation was associated with a higher PVI durability compared to operators with only point-by-point radiofrequency experience (76% vs 60%; P < 0>5 years) and the size of the PFA device used (31 mm vs 35 mm) had no impact on PV lesion durability (29).
The question whether the recurrence rate is directly related to the operator experience with this new technology, contact force applied or frequency of energy delivered needs to be studied in a large-scale randomized study.
c)Different technologies
Another important point that should be considered is that the results of one trial using a certain PFA system are not generalizable and do not necessarily apply to other systems. Unlike thermal energy delivered by RF generators where the effect of lesions is to a far extent predictable, PFE delivery greatly differs between different systems with a lot of parameters that can be modulated by the manufacturer including pulse amplitude, pulse duration, unipolar/bipolar, monophasic/biphasic, interpulse delay, interphase delay, pulse train number and pulse train duration (30). Moreover, the optimal waveform (monophasic or biphasic) regarding safety and efficacy is another point that deserves further studies (26).
4.Available technologies, current evidence, and ongoing trials
a.Farapulse PFA system (Boston Scientific)
Among the currently available systems, the Farapulse PFA system has arguably received the most attention (31) The FDA recently approved ablation system in patients with paroxysmal and persistent atrial fibrillation (AF) after demonstrating favourable safety and efficacy in four controlled prospective trials (IMPULSE, PEFCAT, PEFCAT-2, and PersAFone) (31–33).
The FARAPULSE PFA System is composed of three main components: FARADRIVE™ Steerable Sheath designed for access and navigation, FARAWAVE™ PFA Catheter designed to treat a range of PV anatomies using a 12-F over-the-wire catheter with 5 splines that each contain 4 electrodes, which can be deployed in either a flower or basket configuration (Figure 1) and FARASTAR™ PFA Generator designed for an easy three-button click to PREPARE, CONFIRM and DELIVER therapy using bipolar & biphasic waveforms with proprietary pulses
While the commercially available 12F multispline-electrode catheter FARAWAVE™ PFA Catheter is designed to be used for PVI, the trial design in PEFCAT II and PersAFone also allowed for the use of the 12F deflectable focal PFA catheter (Faraflex, Farapulse Inc.) for CTI, posterior wall of the left atrium (LA), and mitral isthmus ablation.
The first in-human experience with pulsed field AF ablation using Farapulse PFA system was in 2018 by Reddy and his colleagues including 22 patients with symptomatic paroxysmal AF who underwent their first ablation procedure with either endocardial approach (15 patients) or epicardial approach (7 patients). The acute success rate was 100%, where all patients in whom energy was successfully delivered to the tissues had complete electrical isolation and no adverse events were reported neither intraoperative nor after 1 month of follow up (34).
The IMPULSE (A Safety and Feasibility Study of the IOWA Approach Endocardial Ablation System to Treat Atrial Fibrillation] and PEFCAT (A Safety and Feasibility Study of the FARAPULSE Endocardial Ablation System to Treat Paroxysmal Atrial Fibrillation) trials were feasibility studies primarily designed to assess the safety and effectiveness of catheter-based PFA in paroxysmal atrial fibrillation using the over-the- wire, single shot–type multielectrode PFA catheter (Farawave, Farapulse) to achieve PVI. In 81 patients with symptomatic paroxysmal AF, acute success of PV isolation was 100%, with only one adverse event (pericardial tamponade) after 120 days of follow up (1.2%). The durability of lesions was assessed after 3 months by invasive remapping and improved from 18 to 100% with waveform refinement. In addition, the 12-month Kaplan-Meier estimate of freedom from arrhythmia was 87.4 ± 5.6% (35). The PEFCAT II trial also investigated the first-in-human treatment of cavotricuspid isthmus (CTI) dependent flutter with the novel, deflectable focal PFA catheter (Faraflex, Farapulse) in addition to treatment of the PVs (36).
Invasive remapping for patients recruited in these 3 nearly identical trials (IMPULSE, PEFCAT, and PEFCAT II) revealed that durable PVI was achieved in 84.8% of PVs (64.5% of patients) in the entire cohort, and 96.0% of PVs (84.1% of patients) treated with the optimized biphasic energy PFA waveform. Primary adverse events occurred only in 2.5% of patients (2 pericardial effusions or tamponade, 1 hematoma); in addition, there was 1 transient ischemic attack. Furthermore, the 1-year Kaplan-Meier estimates for freedom from any atrial arrhythmia for the entire cohort and for the optimized biphasic energy PFA waveform cohort were 78.5 ± 3.8% and 84.5 ± 5.4%, respectively. This data confirmed that PVI with the flower or basket PFA catheter in paroxysmal AF patients, is safe, efficient, durable, and results in a high rate of freedom from recurrent atrial arrhythmias (36).
Neven and his colleagues reported also six-month follow-up of PVI using PFA for paroxysmal AF confirming that PVI using PFA for paroxysmal AF in a “real-world” setting is safe and feasible with favourable post-ablation clinical course and 6-month follow-up. Only a single participant developed cardiac tamponade, 27 patients (90%) were in normal sinus rhythm on day 90, 3 patients had AF/AT recurrence requiring redo procedure and all 30 patients were free of anti-arrhythmic drugs and in normal sinus rhythm on day 180 (37).
Although retrospective, the MANIFEST-PF survey is the largest multinational survey including cohort of 1758 patients with paroxysmal/persistent AF (58/35%) undergoing PFA at 24 clinical centres by 90 operators using the FARAPULSE system confirming that PFA is efficacious for PVI with favourable safety profile consistent with preferential tissue ablation. The acute success of PVI was as high as 99.9%, with no recorded PFA-related complications; namely persistent phrenic nerve paralysis, symptomatic PV stenosis or oesophageal injuries. Among non PFA-related complications, vascular complications were the most common (3.17%), most of which were minor complications and didn’t require surgical intervention. Cardiac tamponade occurred in 0.97% of cases while the incidence of stroke was 0.39%. Coronary vasospasm with associated ST segment elevation during mitral isthmus ablation was reported in only one patient and subsequently relieved with intracoronary nitroglycerine (38).
The relatively small percentage of patients with persistent AF included in all of the above studies obviated the need for dedicated trials for such population. The PersAFOne trial was a single-arm study aiming to evaluate bipolar biphasic PEF ablation for 25 patients with persistent AF in terms of safety and efficacy (lesion durability for both PVI and left atrial posterior wall ablation) using the Farawave for PVI and the focal PFA catheter; Faraflex for extra PV ablation. Acute success was achieved in 100% (both PVI and left atrial posterior wall ablation) and invasive remapping 2-3 months later revealed durable isolation in 96% of PVs and 100% of left atrial posterior walls. As for the safety outcome, oesophagogastroduodenoscopy (OGD) revealed no oesophageal mucosal lesions and cardiac computerised tomography (CT) scan revealed no PV stenosis (39).
The PersAFOne III t rial is an ongoing prospective multi-center single arm trial which will be studying the safety and feasibility for PFA of persistent AF and associated AFL. The study has a composite primary safety endpoint that is defined as the incidence of early-onset and late-onset device- or procedure-related pre-specified adverse events (40).
Comparing the different thermal ablation approaches, Nakatani and his colleagues prospectively enrolled eighteen of the patients involved in the IMPULSE and PEFCAT trials and compared them to 23 patients undergoing AF ablation by RF (n=16) or cryoablation (n=7) in terms of safety. Cardiac magnetic resonance (CMR) was performed in all patients pre-operatively, < 3 P=0.41),>
b.PulseSelect PFA System (Medtronic)
The PulseSelect PFA System is a new promising investigational PFA system which transmits a controlled biphasic, bipolar waveform to user-selectable electrodes via an over-the-wire, a circular array of 9 gold electrodes (electrode length, 3 mm; 20° forward tilted array with a diameter of 25 mm; 9F shaft) (Figure 1). The circular catheter can also record PV and atrial potentials and perform pacing. The system can deliver a variety of power profiles with voltages applied to the electrodes ranging from 500 to 1500 volts (43).
The PULSED AF pilot trial (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF) was the first in-human multi-center study evaluating the safety and efficacy of this new system. In this first-in-human pilot trial, 35 patients with paroxysmal AF along with 3 patients with persistent AF had their PVs successfully isolated (152/152) with no major adverse events after a 1-month follow up period (44).
The recently published PULSED AF pivotal trial was a prospective, global, multicentre, nonrandomized, paired single-arm study in which patients with paroxysmal (n=150) or persistent (n=150) symptomatic AF refractory to class I or III antiarrhythmic drugs were treated with PFA. All patients were monitored for 1 year using weekly and symptomatic trans-telephonic monitoring. PFA was shown to be effective at 1 year in 66.2% of patients with paroxysmal AF and 55.1% of patients with persistent AF. The primary safety end point occurred in 1 patient in both the paroxysmal and persistent AF cohorts (one cerebrovascular accident in paroxysmal AF cohort and one cardiac tamponade in persistent AF cohort). This pivotal trial demonstrated a low rate of primary safety adverse events (0.7%) and consistent effectiveness using the PulseSelect PFA System (45).
c.Sphere-9 Catheter and Affera Mapping and Ablation System (Medtronic)
The Affera lattice-tip Sphere-9 catheter (Figure 1) is another unique catheter technology which is capable of delivering both RF and PF energies for ablation using same catheter. This catheter can be used within an electroanatomical mapping system (Prism-1, Affera Inc., Newton, MA, USA) and PFA is delivered via the PFA generator (HexaPULSE, Affera, Inc.).
The 7.5 F catheter has an expandable 9-mm lattice nitinol tip, a central indifferent electrode and 9 mini-electrodes, 0.7-mm each, on the spherical surface with temperature sensing capability. In addition, it has an expandable spheroid-shaped lattice tip with a 10-fold larger effective area compared to the conventional 3.5 mm electrode and can deliver higher energy with a lower risk of tissue overheating including linear lesions to mitral isthmus, left atrial roof and cavotricuspid isthmus (46).
The efficacy and safety of such system was studied on a cohort of 76 patients with paroxysmal (n=55) or persistent AF (n=21). The primary feasibility endpoint of acute PV isolation was achieved in 100% of the patients and the primary safety endpoint, defined as a composite of major adverse events within seven days, was achieved in 98.7% of patients with only one patient developed an access-site hematoma that required surgical intervention (47).
The multicentre, prospective, randomised; Treatment of Persistent Atrial Fibrillation with Sphere-9 Catheter and Affera Mapping and Ablation System (SPHERE Per-AF) is an ongoing trial that will test the effectiveness and safety of the Sphere-9 catheter together with the Affera cardiac mapping system in the treatment of persistent AF patients (48).
d.VARIPULSE (Biosense Webster)
Another system which is currently under trial is the VARIPULSE ablation system (Biosense Webster, Inc. Irvine, California) which has recently achieved the CE mark approval for the treatment of symptomatic drug refractory recurrent paroxysmal AF using PFA. This system consists of a novel, mapping-integrated, variable-loop, pulsed field ablation VARIPULSE™ Catheter and TRUPULSE™ PFA generator.
The variable loop circular catheter (VLCC) (figure 1) is a steerable, multielectrode, irrigated catheter. A bidirectional circular tip is attached to the distal end of the 8.5 Fr shaft is which can be expanded and contracted, as necessary, to fit PVs of different sizes. The 10 platinum/iridium electrode rings are used for visualization, stimulation, recording, and bipolar pulsed field ablation. All 10 poles of the VLCC are used for ablation, except in the case of electrode overlap which require the most distal and most proximal electrodes to be turned off (49).
Figure 1: Available PFA systems
The ablation system is designed to be used with the CARTO™ 3 System, enabling mapping integration to the application of PF energy and incorporates proprietary technology to deliver short-duration, high-voltage bipolar biphasic pulses to a multielectrode ablation catheter. Each pulse is delivered as a square wave with positive and negative phases. PFA is applied in a bipolar configuration with an energy of 1800V. Each pulsed field application includes trains of microsecond-long biphasic pulses in between, for a total application duration of approximately 250 microseconds. The generator can also be configured to deliver energy to specific electrode pairs and to adjust energy delivery based on clinical need.
The inspIRE prospective multi-center clinical trial (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by PFA System with Irreversible Electroporation [IRE]) was the first clinical study for the PFA system with full electroanatomical mapping system integration. It assessed the safety and efficacy of the new fully integrated biphasic pulsed field ablation (PFA) VARIPULSE system, which is comprised of a multi-channel generator,
variable decapolar irrigated loop circular VARIPULSE™ Catheter and TRUPULSE™ Generator (Biosense Webster, Inc.) for the treatment of paroxysmal atrial fibrillation (PAF). Across 13 centers, 226 patients were enrolled (wave I-40, wave II-186). No primary adverse events were reported in either cohort and PVI without acute reconnection was achieved in 97.1% of targeted veins. Primary efficacy was achieved in 70.9%, 12-month freedom from symptomatic AF /AFL /AT recurrence and repeat ablation was 78.9% and 92.3%, respectively (50).
Recently, Twelve-month outcomes data from the pilot phase of the admIRE study (Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the Biosense Webster IRE Ablation System) showed that among 20 patients who completed the 12-month follow-up visit, 100
Pulsed field ablation is a new promising technology with a highly selective and tissue-specific mechanism of action that seems to be effective and safe in treating AF patients. Although published studies are so far reassuring confirming safety and efficacy. However, multicentre, randomized controlled studies comparing PFA with other ablation energy sources would be very important to assess the long-term outcomes and recurrence rate.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
